Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery: A real-world, prospective, multicentre, cohort study

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1151-1160

  Mismetti, Patrick ^a   Samama, Charles Marc ^b   Rosencher, Nadia ^c   Vielpeau, Claude ^d   Nguyen, Philippe ^e   Deygas, Beatrice ^f   Presles, Emilie ^f   Laporte, Silvy ^g  

^a UNIVERSITÉ JEAN MONNET   (France)

^b HÔTEL DIEU   (France)

^c Université Paris Descartes ^*  (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Reims University Hospital   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g University Jean Monnet of Saint Etienne EA3065   (France)

Author keywords

Fondaparinux 1.5 mg; Major orthopaedic surgery; Prospective cohort; Renal insufficiency; Venous thromboembolism

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE CLEARANCE; DEATH; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRODUODENAL ULCER; HEMATOMA; HUMAN; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; CREATININE; FEMALE; FRACTURE FIXATION; FRANCE; HEMORRHAGE; HIP FRACTURES; HUMANS; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84861748703     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-09-0640     Document Type: Article

References (34)

1. Monreal M, et al. Venous Thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119: 1073-1079.
2. Geerts WH, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 381S-453S.
3. SFAR 2005. Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale. Recommandations pour la pratique clinique. Available at: http://www. sfar.org/_docs/articles/209-RPC%20MVTE.pdf. Accessed May 24, 2011.
4. Hirsh J, et al. Parenteral Anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 141-159.
5. Cadroy Y, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-390.
6. Goudable C, et al. Pharmacokinetics of a low molecular weight heparin (Fraxipa-rine) in various stages of chronic renal failure. Nephron 1991; 59: 543-545.
7. Sanderink GJ, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231.
8. Rabbat C, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20: 357-363.
9. Stöbe J, et al. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 2006; 44: 455-465.
10. Tincani E, et al. Safety of dalteparin for the prophylaxis of venous thromboembol-ism in elderly medical patients with renal insufficiency: a pilot study. Haemato-logica 2006; 91: 976-979.
11. Mahé I, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative phar-macokinetic study. Thromb Haemost 2007; 97: 581-586.
12. Mahé I, et al. Elderly medical patients treated with prophylactic dosages of enox-aparin: influence of renal function on anti-Xa activity level. Drugs Aging 2007; 24: 63-71.
13. Berges A, et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007; 64: 428-438.
14. Arixtra. Fondaparinux sodium. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_-_Product_Information/human/000403/WC500027746.pdf. Accessed May 24, 2011.
15. Turpie AG, et al. Pharmacokinetic and clinical data supporting the use of fonda-parinux 1.5 mg once daily in the prevention of venous thromboembolism in ren-ally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-121.
16. Fuji T, et al. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008; 32: 443-451.
17. Turpie AG, et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
18. Turpie AG, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
19. Eriksson BI, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
20. Lassen MR, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
21. Eriksson BI, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
22. Eriksson BI, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
23. Rosencher N, et al. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost 2005; 3: 2006-2014.
24. Vera-Llonch M, et al. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006; 117: 569-577.
25. Samama CM, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007; 5: 2360-2367.
26. Singelyn FJ, et al. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT study. Anesth Analg 2007; 105: 1540-1547.
27. Friedman RJ, et al; for the RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous throm-boembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thromb Res 2010; 126: 175-182.
28. Pradaxa (dabigatran etexilate). EMEA/174363/2008. London, 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_as sessment_report/human/000829/WC500041062.pdf. Assessed May 24, 2011.
29. Xarelto (rivaroxaban). EMEA/543519/2008. London, 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_as sessment_report/human/000944/WC500057122.pdf. Accessed May 24, 2011.
30. Schulman S, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 257-298.
31. Lassen MR. Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. J Thromb Haemost 2009; 7: 889-907.
32. Turpie AG, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364-366.
33. Colwell CW Jr, et al. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21: 36-45.
34. Eriksson BI, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304.